GSK-J4 Inhibition of KDM6B Histone Demethylase Blocks Adhesion of Mantle Cell Lymphoma Cells to Stromal Cells by Modulating NF-κB Signaling - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/37566089/
Multiple signaling pathways facilitate the survival and drug resistance of malignant B-cells by regulating their migration and adhesion to microenvironmental niches. NF-κB pathways are commonly dysregulated in mantle cell lymphoma...
Conclusion: KDM6B induces the NF-κB pathway at different levels in MCL, thereby facilitating MCL cell adhesion, survival, and drug resistance. KDM6B represents a novel potential therapeutic target for MCL.
Combating relapsed and refractory Mantle cell lymphoma with novel therapeutic armamentarium: Recent advances and clinical prospects
Source : https://www.sciencedirect.com/science/article/abs/pii/S1040842823001737?via=ihub
Mantle cell lymphoma (MCL) is a rare, aggressive subtype of non-Hodgkin's lymphoma (NHL), accounting for 5% of all cases. Due to its virulence factor,...
Relevance: This article reviews certain therapies that could help update the current approach and summarizes a few miscellaneous agents, which, seldom studied in trials, could alleviate the regression observed in traditional therapies.
Integrative Prognostic Machine Learning Models in Mantle Cell Lymphoma
Patients with mantle cell lymphoma (MCL), an incurable B-cell malignancy, benefit from accurate pretreatment disease stratification. We curated an extensive database of 862 patients diagnosed between 2014 and 2022. A...
Conclusions/Relevance: This work demonstrates the clinical utility of complex ML models and provides further evidence for existing prognostic markers in MCL.
The prognostic value of 19S ATPase proteasome subunits in acute myeloid leukemia and other forms of cancer
Source : https://www.frontiersin.org/articles/10.3389/fmed.2023.1209425/full
IntroductionThe ubiquitin-proteasome system (UPS) is an intracellular organelle responsible for targeted protein degradation, which represents a standard therapeutic target for many different human malignancies. Bortezomib, a reversible inhibitor of chymotrypsin-like...
Discussion: Altogether, our data suggest that components of the 19S proteasome could serve as prognostic biomarkers and novel therapeutic targets in AML and several other human malignancies.
Assessing unmet need among elderly Medicare Beneficiaries with Mantle cell lymphoma: an analysis of treatment patterns, survival, healthcare resource utilization, and costs - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/37497877/
Studies evaluating real-world outcomes and health care utilization for mantle cell lymphoma are limited. We utilized national Medicare claims (2009-2019) to examine treatment patterns, healthcare resource utilization, costs, and survival...
Conclusions/Relevance: These results suggest a large unmet need and future work should evaluate whether novel therapies have improved outcomes among elderly patients with MCL.